<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04581668</url>
  </required_header>
  <id_info>
    <org_study_id>2021-2731</org_study_id>
    <nct_id>NCT04581668</nct_id>
  </id_info>
  <brief_title>Impact of NAVA Ventilation on Brain Oxygenation and Perfusion in Children With Congenital Heart Disease</brief_title>
  <official_title>Impact of NAVA Ventilation on Brain Oxygenation and Perfusion in Children With Congenital Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Justine's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Justine's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Positive intra-thoracic pressures induced by mechanical ventilation can negatively impact&#xD;
      right heart hemodynamics by restricting systemic venous return and increasing right&#xD;
      ventricular afterload. These consequences may be detrimental in patients with a restrictive&#xD;
      right ventricular physiology and in patients with single ventricle physiology. NAVA (Neurally&#xD;
      Adjusted Ventilatory Assist) ventilation decreases intra thoracic pressures compared to&#xD;
      conventional ventilation modes. Brain perfusion is both a hemodynamic indicator and a&#xD;
      prognostic factor in cardiac postoperative care. Diffuse Correlation Spectroscopy (DCS)&#xD;
      coupled with Near Infrared Spectroscopy (NIRS) is a new technology that allows monitoring, in&#xD;
      addition to brain tissue oxygenation, changes in brain blood flow.&#xD;
&#xD;
      This physiological study aims to evaluate the impact of NAVA mode ventilation on cerebral and&#xD;
      systemic hemodynamics in post-operative cardiac surgery patients with preload dependant right&#xD;
      ventricle or with passive venous return to the lungs . This prospective cross-over study will&#xD;
      include 30 patients.&#xD;
&#xD;
      Once stabilized in intensive care, patients will undergo 2 periods of ventilation in NAVA&#xD;
      mode and conventional mode separated by a 30-minute washout period, in a random order.&#xD;
&#xD;
      For each period the following information will be collected: changes in cerebral blood flow&#xD;
      and cerebral oxygenation, hemodynamic parameters including cardiac output and oxygen&#xD;
      transport and ventilatory parameters.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Scientific context&#xD;
&#xD;
           In post-operative cardiac surgery, invasive ventilation is often necessary, but the&#xD;
           induced positive intra thoracic pressures can be detrimental to hemodynamics via several&#xD;
           mechanisms: decrease in venous return, increase in pulmonary vascular resistance and&#xD;
           increase in the afterload of the right ventricle. This effect is particularly&#xD;
           problematic in patients with a restrictive right ventricle, who are preload dependent,&#xD;
           and in patients with cavo pulmonary connections for single ventricle palliation. In&#xD;
           these patients, decreasing ventilator positive pressure improves cardiac output and&#xD;
           cerebral oxygenation. However, very early extubation is not always possible or safe, and&#xD;
           it is therefore essential to optimize mechanical ventilation in order to minimize its&#xD;
           hemodynamic consequences.&#xD;
&#xD;
           In adults, ventilation in NAVA (Neurally Adjusted Ventilatory Assist) mode, regardless&#xD;
           of the level of assistance, allows the preservation of intra thoracic pressure&#xD;
           variations characteristic of spontaneous ventilation and limits the impact of&#xD;
           ventilation on right ventricular ejection. In children, inspiratory and mean pressures&#xD;
           are also lower in NAVA compared to conventional ventilation.&#xD;
&#xD;
           Assessment of brain oxygenation and perfusion in cardiovascular resuscitation is&#xD;
           important both as a hemodynamic parameter and as a neurological prognostic factor. An&#xD;
           innovative non-invasive tool, Diffuse Correlation Spectroscopy coupled with Near&#xD;
           Infrared Spectroscopy (DCS-NIRS), allows the non-invasive evaluation of both cerebral&#xD;
           oxygenation and variations in cerebral blood flow.&#xD;
&#xD;
        2. Hypothesis and objectives&#xD;
&#xD;
           The hypothesis is that the NAVA ventilation mode, which generates lower intra thoracic&#xD;
           pressures than conventional ventilation modes, will improve cerebral hemodynamics,&#xD;
           cardiac output, and oxygen transport of at-risk patients in the post-operative cardiac&#xD;
           surgery setting compared with conventional ventilation.&#xD;
&#xD;
           Main objective:&#xD;
&#xD;
           In pediatric patients following cardiac surgery with risk of right ventricular diastolic&#xD;
           dysfunction or passive pulmonary venous return (including Glenn, hemi-Fontan, Fontan,&#xD;
           and Tetralogy of Fallot surgery), investigators will evaluate the impact of NAVA&#xD;
           ventilation on:&#xD;
&#xD;
             -  cerebral perfusion: cerebral blood flow (mm2/s) measured by DCS.&#xD;
&#xD;
             -  cerebral oxygenation: cerebral tissue saturation (%) and regional cerebral O2&#xD;
                extraction (OEF, measured by NIRS-DCS).&#xD;
&#xD;
           Secondary objective:&#xD;
&#xD;
           In pediatric post-operative cardiac surgery patients with risk of restrictive right&#xD;
           ventricle or passive pulmonary venous return (including Glenn, hemi-Fontan, Fontan, and&#xD;
           Tetralogy of Fallot type surgery), investigators will compare the impact of conventional&#xD;
           ventilation to NAVA mode on:&#xD;
&#xD;
             -  Brain regional O2 consumption extracted from NIRS-DCS measurements&#xD;
&#xD;
             -  Systemic hemodynamics, including cardiac index, lactate level, central venous&#xD;
                oxygen saturation (ScvO2), and oxygen transport&#xD;
&#xD;
             -  Ventilation parameters&#xD;
&#xD;
             -  Comfort as measured by the COMFORT scale&#xD;
&#xD;
        3. Methods&#xD;
&#xD;
      This is a prospective cross-over, single-center, physiological study to be conducted in the&#xD;
      Pediatric Intensive Care Unit of CHU Sainte Justine (Montreal, Canada).&#xD;
&#xD;
      Two periods of 60 minutes in each of 2 ventilation modes will be compared: conventional&#xD;
      ventilation mode (as prescribed by the treating team) and NAVA mode, in random order.&#xD;
&#xD;
      On admission to the PICU postoperatively, study patients will be fitted with a naso-gastric&#xD;
      NAVA probe.&#xD;
&#xD;
      Before performing any study measurements, investigators will wait for patient stabilization,&#xD;
      which is defined by:&#xD;
&#xD;
        -  absence of hemodynamically significant bleeding&#xD;
&#xD;
        -  stabilization of the ventilation parameters&#xD;
&#xD;
        -  stable inotrope dose The order of the 2 ventilation periods will be randomized according&#xD;
           to a previously generated random list.&#xD;
&#xD;
      Study period ventilation will be set as follows:&#xD;
&#xD;
        -  conventional ventilation: ventilation as prescribed by the treating team will be&#xD;
           continued. Usually, ventilation is in PRVC (pressure regulated volume control) mode with&#xD;
           a tidal volume between 5 and 8 mL/kg, a peep between 4 and 5, a respiratory rate to aim&#xD;
           for normocapnia, and FiO2 to aim for PaO2 between 100 and 150 mmHg.&#xD;
&#xD;
        -  NAVA Mode: NAVA level setting to target an Edi level between 3 and 20 V, tidal volume&#xD;
           between 5 and 7 mL/kg, and no respiratory distress on physical examination. The trigger&#xD;
           will be set at 0.5 V. The maximum pressure will be limited to 30 cmH2O. The PEEP level&#xD;
           will not be changed from that prescribed by the treating physician.&#xD;
&#xD;
      To facilitate comparability of brain flow and oxygenation measurements, FiO2, NO&#xD;
      concentration, inotrope dose, and sedation will be kept as stable as possible during these&#xD;
      periods, at the discretion of the treating physician. Similarly, if possible, blood&#xD;
      transfusions will not be administered during the study period.&#xD;
&#xD;
      During the two periods of ventilation, the following parameters will be recorded&#xD;
      continuously:&#xD;
&#xD;
        -  ventilatory parameters: ventilator parameters according to the set mode: peak&#xD;
           inspiratory pressure, mean airway pressure, PEEP, tidal volume, total and spontaneous&#xD;
           minute ventilation, Edi level, FiO2, exhaled CO2 via volumetric capnography.&#xD;
&#xD;
        -  hemodynamic parameters: heart rate (HR), mean arterial pressure, systolic, diastolic,&#xD;
           central venous pressure (CVP), left atrial pressure (LAP), type and dose of vasoactive&#xD;
           medications received with calculation of the vasoactive-inotropic score.&#xD;
&#xD;
      In the second half of each period, investigators will perform:&#xD;
&#xD;
        -  a central arterial and venous blood gas and an arterial lactate measurement.&#xD;
&#xD;
        -  a measurement of cerebral blood flow by diffuse correlation spectroscopy and a&#xD;
           measurement of cerebral regional tissue saturation and oxygen extraction. These&#xD;
           measurements are done non-invasively and painlessly by applying a probe to the child's&#xD;
           forehead for approximately 20 minutes.&#xD;
&#xD;
        -  a limited cardiac ultrasound for the calculation of cardiac output (CO).&#xD;
&#xD;
        -  calculation of urine output during the ventilation period.&#xD;
&#xD;
      In addition, for each patient, the following information will be collected:&#xD;
&#xD;
        -  age at the time of surgery&#xD;
&#xD;
        -  cardiac diagnosis&#xD;
&#xD;
        -  existence and quantification of aorto-pulmonary collaterals&#xD;
&#xD;
        -  preoperative medications&#xD;
&#xD;
        -  operative details: surgical procedure, duration of cardiopulmonary bypass, aortic&#xD;
           cross-clamp duration, inotropes administered (and maximum dose).&#xD;
&#xD;
        -  result of the postoperative trans-esophageal cardiac echo (cardiac function, evaluation&#xD;
           of repair, presence of residual anatomic lesions)&#xD;
&#xD;
        -  arterial and venous blood gases, lactate and haemoglobin levels prior to study&#xD;
           ventilation periods&#xD;
&#xD;
        -  time interval between the end of cardiopulmonary bypass and the start of study&#xD;
           measurements&#xD;
&#xD;
      The variables will be expressed in terms of mean standard deviation or median&#xD;
      (interquartile), depending on the nature of their distribution. Because of the sample size,&#xD;
      analysis of the differences between t variables during the 2 modes of ventilation will be&#xD;
      done using the non-parametric Wilcoxon test (all the variables studied are of the continuous&#xD;
      type). A value of p &lt;0.05 will be considered significant.&#xD;
&#xD;
      For the calculation of sample size, investigators estimated, using the study by Huang et al&#xD;
      (4), that the standard deviation of brain saturation would be 6%, and that the expected&#xD;
      difference between the 2 ventilation modes would be at least 6%. To reach a power of 90% with&#xD;
      an alpha risk set at 0.05, a minimum of 24 patients is required. Given the risk of loss of&#xD;
      sight (e.g. technical difficulty in obtaining the main variable) and due to the heterogeneity&#xD;
      of the patient population, we decided to aim to include 30 patients.&#xD;
&#xD;
      Note that no power calculation based on the variations in cerebral blood flow measured in&#xD;
      spectroscopy was performed, because there was no preliminary data on the subject.&#xD;
&#xD;
      Approval from the Research Ethics Committee of Sainte Justine University Hospital and the&#xD;
      University Medical Affairs Department was obtained. Written consent will be required from the&#xD;
      parents.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 5, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Cross over physiological study with 2 different phases with a 30 minute Wash out period: 30 minutes. Order will be randomized.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brain perfusion</measure>
    <time_frame>30 minutes</time_frame>
    <description>cerebral blood flow measured with diffuse correlation spectroscopy (mm2/s)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain oxygenation</measure>
    <time_frame>30 minutes</time_frame>
    <description>cerebral tissue saturation measured with near-infrared spectroscopy (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain oxygen extraction</measure>
    <time_frame>30 minutes</time_frame>
    <description>Cerebral tissue oxygen extraction measured with near-infrared spectroscopy (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brain regional oxygen consumption</measure>
    <time_frame>30 minutes</time_frame>
    <description>Cerebral tissue oxygen extraction measured with near-infrared spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac output</measure>
    <time_frame>30 minutes</time_frame>
    <description>Cardiac output measured using sub aortic time-velocity integral measured on cardiac ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac index</measure>
    <time_frame>30 minutes</time_frame>
    <description>Cardiac index measured using sub aortic time-velocity integral measured on cardiac ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen transport</measure>
    <time_frame>50 minutes</time_frame>
    <description>According to the following calculation: 1.34 x hemoglobin x SaO2 + 0.0031 x PaO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean airway pressure (cmH2O)</measure>
    <time_frame>60 minutes</time_frame>
    <description>Mean airway pressure (cmH2O) extracted from the ventilator every 30 seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tidal volume</measure>
    <time_frame>60 minutes</time_frame>
    <description>extracted from the ventilator every 30 seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>60 minutes</time_frame>
    <description>extracted from the ventilator every 30 seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minute ventilation</measure>
    <time_frame>60 minutes</time_frame>
    <description>extracted from the ventilator every 30 seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrical activity of the diaphragm</measure>
    <time_frame>60 minutes</time_frame>
    <description>extracted from the ventilator every 30 seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PaO2/FiO2 ratio</measure>
    <time_frame>50 minutes</time_frame>
    <description>Ratio calculated at the end of each ventilation period, based on arterial blood gas</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient comfort</measure>
    <time_frame>60 minutes</time_frame>
    <description>Measured by the COMFORT-B scale (ranges: 6-30, the lowest being the better)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Tetralogy of Fallot</condition>
  <condition>Hypoplastic Left Heart Syndrome</condition>
  <condition>Univentricular Heart</condition>
  <condition>Heart Defects, Congenital</condition>
  <arm_group>
    <arm_group_label>Neurally adjusted ventilatory assist first</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ventilation in NAVA mode then ventilation in conventional mode</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional ventilation first</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ventilation in conventional mode then ventilation in NAVA mode</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neurally adjusted ventilatory assist first</intervention_name>
    <description>Invasive ventilation in Neurally adjusted ventilatory assist during 60 minutes followed by a 30 minutes wash out period then ventilation in conventional mode</description>
    <arm_group_label>Neurally adjusted ventilatory assist first</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional ventilation first</intervention_name>
    <description>Invasive ventilation in conventional mode during 60 minutes followed by a 30 minutes wash out period then ventilation in Neurally adjusted ventilatory assist</description>
    <arm_group_label>Conventional ventilation first</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. admission to the pediatric intensive care unit:&#xD;
&#xD;
               -  after Glenn, Fontan, Fallot Tetralogy surgery&#xD;
&#xD;
               -  or after other types of surgery with risk of post-operative occurence of right&#xD;
                  ventricular failure or low lung output&#xD;
&#xD;
          2. invasive ventilation scheduled for at least 2 hours after admission&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to placement of a nasogastric NAVA tube&#xD;
&#xD;
          -  History of significant focal brain injury (infarction or hemorrhage)&#xD;
&#xD;
          -  Bilateral phrenic paralysis&#xD;
&#xD;
          -  Extubation in operating room or planned to be within the hour,&#xD;
&#xD;
          -  Patient with open chest, uncontrolled shock, need for neuromuscular blockade. Note&#xD;
             that for these criteria, the patient may become eligible when these criteria are&#xD;
             resolved.&#xD;
&#xD;
          -  Patients for whom an acute care limitation order is in place.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume Emeriaud, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Justine's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guillaume Emeriaud, Dr</last_name>
    <phone>514 345 4931</phone>
    <phone_ext>3316</phone_ext>
    <email>guillaume.emeriaud@umontreal.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Genevi√®ve Dupont-Thibodeau, Dre</last_name>
    <phone>514 345 4931</phone>
    <phone_ext>3316</phone_ext>
    <email>genevievedpt@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Justine's Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume Emeriaud, MD, PhD</last_name>
      <phone>514-345-4931</phone>
      <phone_ext>3316</phone_ext>
      <email>guillaume.emeriaud@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Lucy Clayton, MSc</last_name>
      <phone>514-345-4931</phone>
      <phone_ext>6816</phone_ext>
      <email>lucy.clayton@recherche-ste-justine.qc.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 27, 2020</study_first_submitted>
  <study_first_submitted_qc>October 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Justine's Hospital</investigator_affiliation>
    <investigator_full_name>Dr Guillaume Emeriaud</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Tetralogy of Fallot</mesh_term>
    <mesh_term>Hypoplastic Left Heart Syndrome</mesh_term>
    <mesh_term>Univentricular Heart</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

